Melanocortins protect against brain damage and counteract cognitive decline in a transgenic mouse model of moderate Alzheimer׳s disease
- 1 October 2014
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 740, 144-150
Abstract
No abstract availableKeywords
Funding Information
- Department of Biomedical, Metabolic and Neural Sciences (FAR2008, E91J08000630005)
- University of Modena and Reggio Emilia
This publication has 63 references indexed in Scilit:
- Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical EvidenceCNS Drugs, 2013
- Age-Dependent Neuroplasticity Mechanisms in Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid-β LevelsPLOS ONE, 2013
- Preclinical Alzheimer disease—the challenges aheadNature Reviews Neurology, 2012
- Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 miceJournal of Neuroinflammation, 2012
- Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future DirectionsMolecular Neurobiology, 2011
- α-MSH: A Potential Neuroprotective and Immunomodulatory Agent for the Treatment of StrokeJournal of Cerebral Blood Flow & Metabolism, 2010
- Science of Self-PreservationCirculation, 2009
- Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinicThe Lancet Neurology, 2009
- Selective melanocortin MC4receptor agonists reverse haemorrhagic shock and prevent multiple organ damageBritish Journal of Pharmacology, 2007
- Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's diseaseProceedings of the National Academy of Sciences, 2007